Barclays PLC boosted its holdings in GRIFOLS S A/S (NASDAQ:GRFS) by 495,481.8% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 163,542 shares of the biotechnology company’s stock after buying an additional 163,509 shares during the period. Barclays PLC’s holdings in GRIFOLS S A/S were worth $3,278,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of GRFS. Thomas White International Ltd. purchased a new stake in GRIFOLS S A/S in the 2nd quarter worth $84,000. Assetmark Inc. grew its position in shares of GRIFOLS S A/S by 453.8% during the second quarter. Assetmark Inc. now owns 6,363 shares of the biotechnology company’s stock valued at $134,000 after purchasing an additional 5,214 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in shares of GRIFOLS S A/S by 24.2% during the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 7,818 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 1,522 shares in the last quarter. First Light Asset Management LLC purchased a new position in shares of GRIFOLS S A/S during the second quarter valued at about $215,000. Finally, Blackhawk Capital Partners LLC. purchased a new position in shares of GRIFOLS S A/S during the second quarter valued at about $254,000. Institutional investors and hedge funds own 18.18% of the company’s stock.
A number of brokerages have recently weighed in on GRFS. Berenberg Bank upgraded GRIFOLS S A/S to a “buy” rating in a research report on Wednesday, October 30th. Zacks Investment Research upgraded GRIFOLS S A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, November 12th. ValuEngine upgraded GRIFOLS S A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Santander upgraded GRIFOLS S A/S from a “hold” rating to a “buy” rating in a research report on Monday, October 28th. Finally, BidaskClub upgraded GRIFOLS S A/S from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 16th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $20.75.
Shares of GRIFOLS S A/S stock opened at $22.65 on Tuesday. The firm has a market cap of $15.73 billion, a price-to-earnings ratio of 19.36, a PEG ratio of 1.43 and a beta of 1.06. The business has a 50-day moving average price of $21.65 and a 200-day moving average price of $20.82. The company has a quick ratio of 0.96, a current ratio of 2.62 and a debt-to-equity ratio of 1.30. GRIFOLS S A/S has a twelve month low of $17.42 and a twelve month high of $23.10.
The company also recently disclosed a semi-annual dividend, which will be paid on Wednesday, December 11th. Stockholders of record on Tuesday, December 3rd will be given a dividend of $0.169 per share. This is a positive change from GRIFOLS S A/S’s previous semi-annual dividend of $0.15. The ex-dividend date of this dividend is Monday, December 2nd. This represents a dividend yield of 1.3%. GRIFOLS S A/S’s dividend payout ratio (DPR) is presently 14.53%.
GRIFOLS S A/S Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
Featured Story: Golden Cross
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.